Skip to main content

FDA Updates

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Enobosarm Granted Fast-Track FDA Review for AR- and ER-Positive, HER2-Negative Metastatic Breast Cancer

FDA Grants Gedatolisib, a Dual PI3K and mTOR Inhibitor, Fast-Track Review for ER-Positive, HER2-Negative Breast Cancer

5
6
7
8
9
10
11

Page 8 of 33
Results 71 - 80 of 330